Legend Biotech Corporation
LEGN
Rangering i aksjer
#4426
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Aksjekurs
$19.04
Sist synkronisert: 2026-10-20
Markedsverdi
$3.52B
Endring (1 dag)
2.09%
Endring (1 år)
-42.06%
Land
US
Handel Legend Biotech Corporation (LEGN)
Kategori
Healthcare
Antall utestående aksjer for Legend Biotech Corporation (LEGN)
Antall utestående aksjer per June 2026: 187.00M
Ifølge Legend Biotech Corporation sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 187.00M. Ved slutten av December 2023 hadde selskapet 88.04M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Legend Biotech Corporation (LEGN) fra 2017 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 187.00M | 104.54% |
| 2024 | 91.43M | 3.84% |
| 2023 | 88.04M | 10.71% |
| 2022 | 79.52M | 12.91% |
| 2021 | 70.43M | 19.21% |
| 2020 | 59.08M | -10.49% |
| 2019 | 66.00M | 32.01% |
| 2018 | 50.00M | -24.25% |
| 2017 | 66.00M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 35.78% |
US
|
|
| 396.00M | 111.76% |
US
|
|
| 478.91M | 156.10% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -66.75% |
NL
|
